首页 | 本学科首页   官方微博 | 高级检索  
检索        

肝移植受者术后初期万古霉素的药代动力学及药效学研究
引用本文:葛卫红,陈志一,唐勤,谢敏,姚永忠,丁义涛.肝移植受者术后初期万古霉素的药代动力学及药效学研究[J].中国药学杂志,2000,35(1):38-40.
作者姓名:葛卫红  陈志一  唐勤  谢敏  姚永忠  丁义涛
作者单位:南京,210008,南京大学医学院附属鼓楼医院
摘    要: 目的:了解肝移植术后早期并发腹膜炎患者使用万古霉素后的药代动力学、药效学及毒性情况。方法:采用荧光偏振免疫分析仪测定用药前后不同时间血液、腹水和胆汁中万古霉素浓度,并以PKBP-N1药代动力学程序对所测得的药物浓度-时间数据进行拟合,计算药代动力学参数。监测血液、腹水及胆汁中万古霉素谷浓度,同时观察体温、白细胞计数及肝、肾功能等药效和毒性指标。结果:该患者静滴万古霉素后的药代动力学过程,在血中符合开放型三房室模型,其药代动力学参数 t1/2aa=5.7min,t1/2β=43min,t1/2rr=9.24h,Vss=19881,cmax=31.29μg·ml-1,cmin=9.07μg·ml-1,Vc=15.981,CL=1.621·h-1;在腹水中符合一房室吸收模型,Ka=0.74,t1/2=8.32h,cmax=20.52μg·ml-1,cmin=10.85μg·ml-1;在胆汁中的药时数据难以用PKBP-N1程序进行拟合。万古霉素谷浓度值血中为(12.58±2.59)μg·ml-1,腹水中为(15.30±1.52)μg·ml-1时,能很快缓解患者腹膜炎的临床症状,无肝肾毒性表现。胆汁中的万古霉素谷浓度较低,为(3.11±0.52)μg·ml-1,不能达到有效的治疗浓度。结论:该患者使用万古霉素后的药代动力学参数与健康正常人无显著差异。在使用万古霉素时应监测血药浓度,实施个体化给药方案,以保证用药安全有效。胆囊感染时不宜用万古霉素治疗。

关 键 词:肝移植受者  万古霉素  药代动力学  药效学
收稿时间:1999-08-20;
修稿时间:1999-08-20

Pharmacokinetics and pharmacodynamics of vancomycin in the liver trans planting operation recevier at the initial stage
Ge Weihong ,Chen Zhiyi ,Tang Qin.Pharmacokinetics and pharmacodynamics of vancomycin in the liver trans planting operation recevier at the initial stage[J].Chinese Pharmaceutical Journal,2000,35(1):38-40.
Authors:Ge Weihong  Chen Zhiyi  Tang Qin
Institution:Ge Weihong (Ge WH),Chen Zhiyi (Chen ZY),Tang Qin (Tang Q) (Nanjing University medical college auxiliary Gulou Hospital,Nan jing,210008)
Abstract:OBJECTIVE:To investigate the Pharmacokinetics,pharm acodynamics and toxicity it of vancomycin in fatients after liver transplanterat ion with peritonitis. METHODS:Using TDX to analyse concentration of vancomycin in p lasma,ascites and bile before and after using the medicine,to fit the concentrat ion vs. time data with the computer software package PKBP-N1, and to calculate the parametes of pharmacodynamics. Monitoring the trough concentrations of van comycin in plasma,ascites and bile and observing the temperature, count of white blood cell, and functions of liver and kidney. RESULT:Pharmacokinetic parameters of vancomycin for the patie nts were in plasma: t1/2α=5.7 min, t1/2β=43 min, t1/2γ=9.24 h, Vss=19.881, cmax=31.29 μg.ml-1, cmin=9.07 μg.ml-1, Vc=15.981, CL =1.621.h-1;in ascite: Ka=0.74, t1/2=8.32 h, c max=20.52 μg.ml-1, cmin=10.85 μg.ml-1. It w as difficult to fit concentrations vs. time data of the medicine in bile with t he programme of PKBP-N1. When the trough concentrations of vancomycin in plasm a was (12.58±2.59)μg.ml-1, it quickly relieved clinical symptom of pe ritonitis without toxicity in liver and kidney. The concentration of vancomycin in bile was low and it did not achieve the effective concentration. CONCLUSION:The pharmacokinetics parameter of vancomycin had no obvious difference with that of the healthy people.The concentrations of pla sma should be monitored when taking vancomycin to ensure applied safety and effi cacy.Vancomycin should not be used when gallbladder was infected.
Keywords:liver transplantation  vancomycin  pharmacokinetics  pharmacodynamics
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中国药学杂志》浏览原始摘要信息
点击此处可从《中国药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号